129 related articles for article (PubMed ID: 11113392)
1. Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice.
Kinoshita T; Kobayashi S; Ebara S; Yoshimura Y; Horiuchi H; Tsutsumimoto T; Wakabayashi S; Takaoka K
Bone; 2000 Dec; 27(6):811-7. PubMed ID: 11113392
[TBL] [Abstract][Full Text] [Related]
2. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.
Yao W; Tian XY; Chen J; Setterberg RB; Lundy MW; Chmielzwski P; Froman CA; Jee WS
J Musculoskelet Neuronal Interact; 2007; 7(2):119-30. PubMed ID: 17627081
[TBL] [Abstract][Full Text] [Related]
3. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Liang L; Beshay E; Prud'homme GJ
Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
[TBL] [Abstract][Full Text] [Related]
4. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
Beshay E; Croze F; Prud'homme GJ
Clin Immunol; 2001 Feb; 98(2):272-9. PubMed ID: 11161985
[TBL] [Abstract][Full Text] [Related]
5. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity.
Diaz-Granados N; Howe K; Lu J; McKay DM
Am J Pathol; 2000 Jun; 156(6):2169-77. PubMed ID: 10854237
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of bone morphogenetic protein-2-induced new bone formation in mice by the phosphodiesterase inhibitor pentoxifylline.
Horiuchi H; Saito N; Kinoshita T; Wakabayashi S; Tsutsumimoto T; Takaoka K
Bone; 2001 Mar; 28(3):290-4. PubMed ID: 11248659
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of recombinant human bone morphogenetic protein-2 (rhBMP-2)-induced new bone formation by concurrent treatment with parathyroid hormone and a phosphodiesterase inhibitor, pentoxifylline.
Horiuchi H; Saito N; Kinoshita T; Wakabayashi S; Tsutsumimoto T; Otsuru S; Takaoka K
J Bone Miner Metab; 2004; 22(4):329-34. PubMed ID: 15221490
[TBL] [Abstract][Full Text] [Related]
9. Rolipram and pentoxifylline combination ameliorates the morphological abnormalities of dorsal root ganglion neurons in experimental diabetic neuropathy by reducing mitochondrial dysfunction and apoptosis.
Dastgheib M; Falak R; Moghaddam MV; Hassanzadeh G; Safa M; Hosseini A
J Biochem Mol Toxicol; 2023 Nov; 37(11):e23459. PubMed ID: 37431890
[TBL] [Abstract][Full Text] [Related]
10. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Harada D; Tsukumo Y; Takashima Y; Manabe H
Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs.
Porwal K; Pal S; Bhagwati S; Siddiqi MI; Chattopadhyay N
Eur J Pharmacol; 2021 May; 899():174015. PubMed ID: 33711307
[TBL] [Abstract][Full Text] [Related]
13. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors.
Souness JE; Houghton C; Sardar N; Withnall MT
Biochem Pharmacol; 1999 Sep; 58(6):991-9. PubMed ID: 10509751
[TBL] [Abstract][Full Text] [Related]
14. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.
Cherry JA; Thompson BE; Pho V
Biochim Biophys Acta; 2001 Mar; 1518(1-2):27-35. PubMed ID: 11267656
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Badger AM; Olivera DL; Esser KM
Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
[TBL] [Abstract][Full Text] [Related]
16. Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
Muravyov AV; Bulaeva SV; Tikhomirova IA; Zamishlayev AV; Uzikova EV; Miloradov MJ
Clin Hemorheol Microcirc; 2011; 49(1-4):431-9. PubMed ID: 22214714
[TBL] [Abstract][Full Text] [Related]
17. Effect of the phosphodiesterase 4 inhibitor, rolipram, on retinoic acid-increased alkaline phosphatase activity in the mouse fibroblastic C3H10T1/2 cell line.
Murata T; Sugatani T; Shimizu K; Manganiello VC; Tagawa T
Arch Oral Biol; 2003 Jan; 48(1):63-7. PubMed ID: 12615143
[TBL] [Abstract][Full Text] [Related]
18. A phosphodiesterase inhibitor, pentoxifylline, enhances the bone morphogenetic protein-4 (BMP-4)-dependent differentiation of osteoprogenitor cells.
Tsutsumimoto T; Wakabayashi S; Kinoshita T; Horiuchi H; Takaoka K
Bone; 2002 Sep; 31(3):396-401. PubMed ID: 12231412
[TBL] [Abstract][Full Text] [Related]
19. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
